- Home
- KYMR vs BHC Comparison
KYMR vs BHC Comparison
Compare KYMR & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- BHC
- Stock Information
- Founded
- KYMR 2015
- BHC N/A
- Country
- KYMR United States
- BHC Canada
- Employees
- KYMR N/A
- BHC N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- KYMR Health Care
- BHC Health Care
- Exchange
- KYMR Nasdaq
- BHC Nasdaq
- Market Cap
- KYMR 2.7B
- BHC 2.9B
- IPO Year
- KYMR 2020
- BHC N/A
- Fundamental
- Price
- KYMR $36.81
- BHC $7.31
- Analyst Decision
- KYMR Buy
- BHC Hold
- Analyst Count
- KYMR 15
- BHC 5
- Target Price
- KYMR $55.27
- BHC $7.20
- AVG Volume (30 Days)
- KYMR 456.1K
- BHC 3.2M
- Earning Date
- KYMR 02-27-2025
- BHC 02-19-2025
- Dividend Yield
- KYMR N/A
- BHC N/A
- EPS Growth
- KYMR N/A
- BHC N/A
- EPS
- KYMR N/A
- BHC N/A
- Revenue
- KYMR $87,563,000.00
- BHC $9,625,000,000.00
- Revenue This Year
- KYMR N/A
- BHC $10.68
- Revenue Next Year
- KYMR $32.89
- BHC $3.66
- P/E Ratio
- KYMR N/A
- BHC N/A
- Revenue Growth
- KYMR 86.92
- BHC 9.91
- 52 Week Low
- KYMR $29.24
- BHC $3.96
- 52 Week High
- KYMR $53.27
- BHC $11.46
- Technical
- Relative Strength Index (RSI)
- KYMR 42.51
- BHC 56.03
- Support Level
- KYMR $36.67
- BHC $6.12
- Resistance Level
- KYMR $38.24
- BHC $7.49
- Average True Range (ATR)
- KYMR 1.78
- BHC 0.31
- MACD
- KYMR 0.06
- BHC 0.07
- Stochastic Oscillator
- KYMR 51.81
- BHC 86.86
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.